Sanguine Resources

News | Events | Case Studies | Spotlight

Monitoring Systemic Lupus Erythematosus Longitudinally

Systemic lupus erythematosus (SLE), also known as lupus, is a chronic autoimmune disease caused by random or inherited mutations in various genes of the immune system. It affects the skin, joints, kidneys, brain, and almost every other organ. People suffering from SLE experience inflammation in the connective tissues that provide strength and flexibility to structures throughout the body.

Recovered Coronavirus Patient Donates Blood To Help Vaccine, Treatment Research

WBZ | CBS Boston – Lara Woolfson’s COVID-19 story and her participation with Sanguine for her in-home blood sample collection. Transcript: Headline News: Live from the Channel 4 Studios in Boston, this is WBZ news at 5:30. Liam Martin: Well for a photographer from Boston who has already recovered from the coronavirus is hoping that her fight with it will help others recover as well.

PODCAST: The Bio Report: Bringing the Trial to the Patient

One of the challenges to securing the participation of patients in clinical trials can be simple geography. Sanguine Biosciences is seeking to tear down that barrier to participation by using mobile technology to bring clinical trials to patients. The company recently partnered with Vir Biotechnology to complete a COVID-19 clinical study aimed at better understanding the biology of the disease by sending healthcare personnel to collect blood samples from patients at their homes.

Same Day Collection and Delivery Key Facts

Certain disease studies exploring sensitive biomarkers or molecules with a short half-life require blood analysis soon after collection to prevent important blood components from breaking down, which may have a negative effect on study results. Numerous factors such as diet, medications, supplements, and patient hydration can affect blood test results.

San Francisco Chronicle

Antibodies in recovered victums’ blood may hold key to COVID-19 cure In the race to develop treatments for the coronavirus, two California biotech companies are teaming up to collect blood samples from people who have recovered from COVID-19 — with the hope that antibodies produced by their immune system after being infected can provide the key to developing a drug or vaccine.

Overcoming Barriers to Clinical Research (White Paper)

The largest barrier to conducting clinical research is the high cost. According to the Tufts Center for the Study of Drug Development (CSDD), it now costs up to $2.6 billion to bring a new drug to market, up from $1 billion from the 1990s to the early 2000s, and costs are continuing to rise.

Researching Rheumatoid Arthritis

Rheumatoid arthritis (RA) is an autoimmune disorder characterized by joint swelling, pain, and damage from chronic inflammation. RA occurs in roughly 5 per 1,000 people and may cause severe and irreversible joint damage and debilitation1. The key to combating RA is early diagnosis and treatment with various anti-inflammatory agents collectively known as disease-modifying antirheumatic drugs (DMARDs), which can prevent or slow joint damage in 90% of patients.

Hepatitis B Infection

Hepatitis B virus (HBV) is the world’s most common cause of chronic viral infection. Individuals may become infected through contact with bodily fluids or from mother to child during birth. Some people with acute HBV infections experience symptoms like vomiting, yellowish skin, dark urine, fatigue, and abdominal pain, while others feel no symptoms at all.

Remote Collection for Duchenne Muscular Dystrophy Research

People with Duchenne muscular dystrophy (DMD) suffer from a range of muscular issues, including a loss of motor, pulmonary, and cardiac functions, which eventually leads to death. Early signs of the disease include developmental delays, enlarged calf muscles, a waddling gait, generalized muscle weakness, and difficulty performing physical activities.

Universal Protocol: An Enhanced Biorepository

Biobanks store various biological samples for research use. Although they have become an important resource for researchers since their introduction in the late 1990s, biobanks provide limited samples and associated information. Sanguine sought to overcome challenges commonly encountered with biobanks by creating a universal protocol for delivering quality standardized biospecimens to the biomedical research community.